Intensity Therapeutics (INTS) & Its Rivals Critical Review

Intensity Therapeutics (NASDAQ:INTS) is one of 610 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its competitors? We will compare Intensity Therapeutics to similar companies based on the strength of its profitability, institutional ownership, valuation, earnings, risk, analyst recommendations and dividends.

Profitability

This table compares Intensity Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Intensity Therapeutics Competitors	-811.78%	-695.88%	-28.43%

Insider & Institutional Ownership

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 7.1% of Intensity Therapeutics shares are owned by insiders. Comparatively, 12.5% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Intensity Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Intensity Therapeutics	N/A	-$11.61 million	-0.77
Intensity Therapeutics Competitors	$861.58 million	$60.72 million	-29.01

Intensity Therapeutics’ competitors have higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Intensity Therapeutics has a beta of 2.94, indicating that its stock price is 194% more volatile than the S&P 500. Comparatively, Intensity Therapeutics’ competitors have a beta of 1.07, indicating that their average stock price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Intensity Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	2	1	2.75
Intensity Therapeutics Competitors	8515	13218	40428	1393	2.55

Intensity Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 748.42%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 67.14%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Intensity Therapeutics is more favorable than its competitors.

Summary

Intensity Therapeutics beats its competitors on 7 of the 13 factors compared.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.